Pursuit Attractions and Hospitality, Inc. (PRSU)
NYSE: PRSU · Real-Time Price · USD
28.37
-1.87 (-6.18%)
At close: Aug 1, 2025, 4:00 PM
28.37
0.00 (0.00%)
After-hours: Aug 1, 2025, 4:10 PM EDT
Oncternal Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Oncternal Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $29.67, which forecasts a 4.58% increase in the stock price over the next year. The lowest target is $10 and the highest is $41.
Price Target: $29.67 (+4.58%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 29, 2025.
Analyst Ratings
The average analyst rating for Oncternal Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Initiates $38 | Strong Buy | Initiates | $38 | +33.94% | May 29, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | -64.75% | May 22, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $50 → $41 | Buy | Maintains | $50 → $41 | +44.52% | May 13, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $54 → $50 | Buy | Reiterates | $54 → $50 | +76.24% | Feb 20, 2025 |
Financial Forecast
Revenue This Year
418.47M
from 366.49M
Increased by 14.18%
Revenue Next Year
448.90M
from 418.47M
Increased by 7.27%
EPS This Year
0.79
from 12.84
Decreased by -93.84%
EPS Next Year
1.08
from 0.79
Increased by 36.77%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 441.5M | 488.8M | 489.5M |
| Avg | 418.5M | 448.9M | 469.0M |
| Low | 396.4M | 418.9M | 444.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 20.5% | 16.8% | 9.0% |
| Avg | 14.2% | 7.3% | 4.5% |
| Low | 8.2% | 0.1% | -1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.10 | 1.32 | 1.59 |
| Avg | 0.79 | 1.08 | 1.49 |
| Low | 0.62 | 0.89 | 1.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -91.4% | 67.4% | 46.6% |
| Avg | -93.8% | 36.8% | 38.2% |
| Low | -95.2% | 12.8% | 28.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.